| ‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA |
| A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19 |
| A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications |
| A Closer Look at N1-methylpseudouridine in the Modified mRNA Injectables |
| A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells |
| A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States |
| A Potential Role of the Spike Protein in Neurodegenerative Diseases: A Narrative Review |
| A Report on the U.S. Vaccine Adverse Events Reporting System (VAERS) of the COVID-19 Messenger Ribonucleic Acid (mRNA) Biologicals |
| Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis |
| Adverse effects of COVID-19 vaccines and measures to prevent them |
| Affidavit of LTC. Theresa Long M.D. in Support of a Motion for a Preliminary Injunction Order |
| All Cause Mortality and COVID-19 Injections: Evidence from 28 Weeks of Public Health England “COVID-19 Vaccine Surveillance Reports” |
| Alternate mechanisms of mRNA vaccine toxicity: which one is the main culprit? |
| Amyloidogenesis of SARS-CoV-2 Spike Protein |
| An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies |
| Anaphylaxis-Induced Acute Coronary Syndrome Following Covid-19 mRNA-LNP Vaccination: Mechanisms and Therapeutic Approaches |
| Antiviral treatments [Molnupiravir] lead to the rapid accrual of hundreds of SARS-CoV-2 mutations in immunocompromised patients |
| Antiviral, virucidal and antioxidant properties of Artemisia annua against SARS-CoV-2 |
| Autoimmune and Neoplastic Outcomes After the mRNA Vaccination: The Role of T Regulatory Cell Responses |
| Cardiac side effects of RNA-based SARS-CoV-2 vaccines: Hidden cardiotoxic effects of mRNA-1273 and BNT162b2 on ventricular myocyte function and structure |
| CDC REMOVES Their Claim That mRNA & Spike Protein "Do Not Last Long In The Body” |
| Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2 - A Multidisciplinary Perspective |
| Chemical-physical criticality and toxicological potential of lipid nanomaterials contained in a COVID-19 mRNA vaccine |
| Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis |
| Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis |
| Clinical Approach to Post-acute Sequelae After COVID-19 Infection and Vaccination |
| Clinical Rationale for SARS-CoV-2 Base Spike Protein Detoxification in Post COVID-19 and Vaccine Injury Syndromes |
| Comirnaty Facts: Mechanisms of action and damage potential |
| Comparative analysis of within-host diversity among vaccinated COVID-19 patients infected with different SARS-CoV-2 variants |
| Concerns regarding Transfusions of Blood Products Derived from Genetic Vaccine Recipients and Proposals for Specific Measures |
| COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 1 |
| COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 2 |
| COVID-19 Vaccine: Critical Questions with Complicated Answers |
| COVID-19 vaccines – An Australian Review |
| Critical appraisal of multidrug therapy in the ambulatory management of patients with COVID-19 and hypoxemia |
| Delayed Induction of Noninflammatory SARS-CoV-2 Spike-Specific IgG4 Antibodies Detected 1 Year After BNT162b2 Vaccination in Children |
| Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS-CoV-2: Possible molecular mechanisms |
| Differences in Vaccine and SARS-CoV-2 Replication Derived mRNA: Implications for Cell Biology and Future Disease |
| DNA fragments detected in monovalent and bivalent Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: Exploratory dose response relationship with serious adverse events. |
| Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease 2019 |
| Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 Omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5 |
| Emergence of a New Creutzfeldt-Jakob Disease: 26 Cases of the Human Version of Mad-Cow Disease, Days After a COVID-19 Inj |
| Endonuclease fingerprint indicates a synthetic origin of SARS-CoV-2 |
| Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein |
| Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients |
| Excess Deaths in the United Kingdom: Midazolam and Euthanasia in the COVID-19 Pandemic |
| Expert testimony of Dr. Christina Parks, PhD |
| Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice |
| Fauci on Antibody Dependent Enhancement (ADE) |
| Faulty predictions by computer simulation may have promoted ineffective public health policies during COVID-19 |
